How Many Quest Diagnostics Incorporated (NYSE:DGX)’s Analysts Are Bullish?

Quest Diagnostics Incorporated (NYSE:DGX) Logo
Investors sentiment decreased to 1.12 in 2019 Q2. Its down 0.10, from 1.22 in 2019Q1. It turned negative, as 32 investors sold Quest Diagnostics Incorporated shares while 169 reduced holdings. 59 funds opened positions while 166 raised stakes. 115.81 million shares or 0.76% less from 116.69 million shares in 2019Q1 were reported.
Ferguson Wellman Mngmt reported 0.01% stake. Baldwin Brothers Ma invested in 400 shares. Trust Co Of Vermont stated it has 0.01% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Sun Life Fin reported 108 shares. 9,472 are held by Canada Pension Plan Board. Tci Wealth Advisors owns 0% invested in Quest Diagnostics Incorporated (NYSE:DGX) for 5 shares. Meag Munich Ergo Kapitalanlagegesellschaft Mbh stated it has 8,302 shares or 0.07% of all its holdings. Jpmorgan Chase & accumulated 159,916 shares or 0% of the stock. Rampart Investment Management Lc holds 0.02% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX) for 1,560 shares. Lord Abbett & Company Ltd Llc has invested 0.11% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Brinker stated it has 0.31% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). The New York-based Alliancebernstein Limited Partnership has invested 0.03% in Quest Diagnostics Incorporated (NYSE:DGX). Australia-based Macquarie Grp Inc has invested 1.4% in Quest Diagnostics Incorporated (NYSE:DGX). Brandywine Glob Mgmt Llc reported 0.08% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Pggm Invests reported 0.27% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX).

Quest Diagnostics Incorporated (NYSE:DGX) Ratings Coverage

Among 6 analysts covering Quest Diagnostics (NYSE:DGX), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. Quest Diagnostics has $12100 highest and $8500 lowest target. $105.50’s average target is 1.05% above currents $104.4 stock price. Quest Diagnostics had 15 analyst reports since March 16, 2019 according to SRatingsIntel. JP Morgan maintained the shares of DGX in report on Wednesday, July 24 with “Neutral” rating. The firm has “Overweight” rating given on Friday, August 23 by Morgan Stanley. On Monday, July 15 the stock rating was downgraded by Goldman Sachs to “Sell”. The stock of Quest Diagnostics Incorporated (NYSE:DGX) has “Buy” rating given on Wednesday, July 24 by Canaccord Genuity. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, April 24. Credit Suisse maintained the stock with “Neutral” rating in Wednesday, July 24 report. As per Wednesday, April 24, the company rating was maintained by UBS. The firm has “Overweight” rating by Morgan Stanley given on Thursday, April 25. The stock of Quest Diagnostics Incorporated (NYSE:DGX) has “Overweight” rating given on Wednesday, July 24 by Morgan Stanley. Below is a list of Quest Diagnostics Incorporated (NYSE:DGX) latest ratings and price target changes.

23/08/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $111.0000 New Target: $121.0000 Maintain
24/07/2019 Broker: JP Morgan Rating: Neutral Old Target: $100.0000 New Target: $111.0000 Maintain
24/07/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $104.0000 New Target: $111.0000 Maintain
24/07/2019 Broker: Canaccord Genuity Rating: Buy Old Target: $108.0000 New Target: $112.0000 Maintain
24/07/2019 Broker: Credit Suisse Rating: Neutral Old Target: $99.0000 New Target: $105.0000 Maintain
15/07/2019 Broker: Goldman Sachs Old Rating: Neutral New Rating: Sell Old Target: $90.0000 New Target: $85.0000 Downgrade
25/06/2019 Broker: Deutsche Bank Rating: Hold Maintain
10/05/2019 Broker: BidaskScore Rating: Sell Upgrade
25/04/2019 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $98.0000 New Target: $104.0000 Maintain
24/04/2019 Broker: UBS Rating: Neutral Old Target: $91.0000 New Target: $99.0000 Maintain

The stock decreased 0.54% or $0.57 during the last trading session, reaching $104.4. About 795,229 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has declined 4.62% since September 13, 2018 and is downtrending. It has underperformed by 4.62% the S&P500.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $14.06 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 19.69 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

More notable recent Quest Diagnostics Incorporated (NYSE:DGX) news were published by: Seekingalpha.com which released: “Stocks To Watch: Apple, IPOs And German Auto – Seeking Alpha” on September 07, 2019, also Seekingalpha.com with their article: “Quest Diagnostics Q2 2019 Earnings Preview – Seeking Alpha” published on July 22, 2019, Finance.Yahoo.com published: “Can You Imagine How Quest Diagnostics’s (NYSE:DGX) Shareholders Feel About The 62% Share Price Increase? – Yahoo Finance” on August 13, 2019. More interesting news about Quest Diagnostics Incorporated (NYSE:DGX) were released by: Finance.Yahoo.com and their article: “Is Quest Diagnostics Incorporated’s (NYSE:DGX) CEO Salary Justified? – Yahoo Finance” published on May 31, 2019 as well as Finance.Yahoo.com‘s news article titled: “Is Quest Diagnostics Incorporated (NYSE:DGX) Better Than Average At Deploying Capital? – Yahoo Finance” with publication date: July 24, 2019.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.